Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 174   

Articles published

PFE 34.80 +0.27 (0.78%)
price chart
Pfizer, Lilly to Resume Studies of Pain Treatment Tanezumab
Pfizer Inc. and Eli Lilly & Co. plan to resume a Phase 3 trial of pain treatment tanezumab after the U.S. Food and Drug Administration lifted a partial clinical hold placed on the program in 2012.
Pfizer, Lilly to resume study testing pain drug  Reuters
Pfizer Inc, Eli Lilly To Recommence Phase 3 Trials For Pain Drug Tanezumab  Bidness ETC
Pfizer Inc. (PFE) Tops DJIA Gainers for March 23
The Dow closed at 18,116.00 on Monday, which is a -0.06% move from yesterday's close. Pfizer Inc. led all gainers with a 2.34% jump.
Pfizer Inc. (PFE) Closes 1.08% Up on the Day for March 27
Pfizer Inc. currently has a total float of 6.13 billion shares and moves 28.94 million a day, on average. The stock opened at $34.44 on March 27 and traded between a low of $34.23 and a high of $34.60.
Pfizer Inc, Eli Lilly, AstraZeneca plc and Bristol-Myers Squibb See Increase ...
The prescription data by Symphony Health, complied by Bloomberg analysts, Michael Shah and Sam Fazeli, shows impressive growth in sales of the drugs manufactured by US pharmaceutical giants including Pfizer Inc. (NYSE:PFE), Eli Lilly & Co.
Travelers Companies Becomes #5 Most Shorted Dow Stock, Replacing Pfizer
In our new rank based on the most recent short interest data from NASDAQ, Travelers Travelers Companies Inc (NYSE: TRV) has taken over the position of #5 most shorted Dow component, from Pfizer Pfizer Inc (NYSE: PFE) which is now in the #6 spot.
One Put, One Call Option To Know About for Pfizer
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Inc (Symbol: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from the July ...
Jefferies Raises Pfizer PT, Says Company Has Multiple Ways To Win
Jefferies on Monday issued a report on Pfizer Inc. (NYSE: PFE), raising its price target from $42 to $45. Jefferies rates Pfizer as a Buy.
Pfizer Inc. (PFE) StockTo Appreciate Significantly, Says Jefferies  Bidness ETC
Drug News Has Pfizer Inc. (PFE) Options in High Demand  Schaeffers Research (blog)
Billionaire Ken Fisher's Top Long-Term Picks: Pfizer Inc., Visa Inc., and More
Billionaire Ken Fisher's Fisher Asset Management maintains a broad and diversified equity portfolio consisting primarily of long positions.
Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 ...
Pfizer Inc. (PFE) announced today the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results ...
Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study  Zacks.com
Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog  Nasdaq
Interesting June Stock Options for Pfizer
So unless Pfizer Inc sees its shares decline 7.7% and the contract is exercised (resulting in a cost basis of $31.58 per share before broker commissions, subtracting the 42 cents from $32), the only upside to the put seller is from collecting that ...